A comparison of three initial antiretroviral AIDS regimens. Antiretroviral therapy: when and what to start-- an American perspective. Other serious complications of shigellosis can include seizure, reactive arthritis and hemolytic uremic syndrome (which affects the kidneys), CDC experts said on the call. (editorial), Three- vs four-drug antiretroviral regimen for the initial treatment of HIV-1 infection: a randomized controlled trial, Gulick RM, Ribaudo HJ, Shikuma CM, Lalama C, Schackman BR, Meyer III WA, Acosta EP, Schouten J, Squires KE, Pilcher CD, Murphy RL, Koletar SL, Carlson M, Reichman RC, Bastow B, Klingman KL, Kuritzkes DR. Design issues in initial HIV-treatment trials: focus on ACTG A5095. Alice K. Pau, Judith A. Aberg, Jason V. Baker, Pamela S. Belperio, Craig M. Coopersmith, Page Crew, Birgit Grund, Roy M. Gulick, Carly Harrison, Arthur Y. Kim, H. Clifford Lane, Henry Masur, Virginia Sheikh, Kanal Singh, Jinoos Yazdany, Pablo Tebas. The HIV Congress is an annual gathering of the top . Irini Sereti, Roy M. Gulick, Sonya Krishnan, Stephen A. Migueles, Adrian Palfreeman, Veronique Touzeau-Rmer, Waldo H. Belloso, Sean Emery, Matthew Law. He graduated with honors from Midwestern University, Chicago College Of Osteopathic Med in 1972. Antiretroviral Therapy: When and What to Start-- An American Perspective. United Healthcare - Direct Choice Plus POS, Find Continuing Care Retirement Communites. Structured treatment interruption in HIV-infected patients: a new approach to treatment? When to switch and what to switch to: strategic use of antiretroviral therapy. There are established guidelines for using common antibiotics to treat shigellosis, but the obvious challenge is that emerging extensively drug-resistant shigella strains are resistant to all of these recommended agents, Dr. Louise Francois Watkins, medical officer with the National Antimicrobial Resistance Monitoring System for Enteric Bacteria Team, said on the CDC call. Learn about the common causes and when to seek medical attention. Rao, Reem Berro, Roy M. Gulick, John P. Moore, Athe M. N. Tsibris, Daniel R. Kuritzkes, Evaluating the Effect of Early Versus Late ARV Regimen Change if Failure on an Initial Regimen: Results From the AIDS Clinical Trials Group Study A5095, Li Li, Joseph J. Eron, Heather J. Ribaudo, Roy M. Gulick, Brent A. Johnson. Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols. 9-Tetrahydrocannabinol Suppresses Secretion of IFN by Plasmacytoid Dendritic Cells From Healthy and HIV-Infected Individuals. Seth Lederman, Roy M. Gulick, Leonard Chess, Dextran sulfate and heparin interact with CD4 molecules to inhibit the binding of coat protein (gp120) of human immunodeficiency virus. Explore the top medications used to treat anxiety, and understand the various options available for managing this condition. In his early career, he worked as a biologist in the Medicinal Chemistry Laboratory at the National Institutes of Health in Bethesda, MD. Little, Anne Y. Liu, Lopez Aj, Mona R. Loutfy, Loy D, Mohammed Dy, Man A, Michael K. Mansour, Vincent C. Marconi, Martin Markowitz, R. Marques, Jeffrey N. Martin, Hal Martin, Kenneth H. Mayer, MJ McElrath, McGhee Ta, Barbara H. McGovern, Katherine McGowan, McIntyre D, Mcleod Gx, Menezes P, Mesa G, Craig E. Metroka, Dirk Meyer-Olson, Miller Ao, Montgomery K, Karam Mounzer, Ellen H. Nagami, Nagin I, Nahass Rg, Nelson Mo, Nielsen C, Norene Dl, David H. OConnor, Bisola O. Ojikutu, Jason F. Okulicz, Oladehin Oo, Oldfield Ec rd, Susan Olender, Mario A. Ostrowski, William F. Owen, Pae E, Parsonnet J, Pavlatos Am, Perlmutter Am, Pierce Mn, Pincus Jm, Pisani L, Price Lj, Laurie A. Proia, Prokesch Rc, Pujet Hc, Moti Ramgopal, Almas Rathod, Rausch M, Ravishankar J, Frank S. Rhame, Richards Cs, Douglas D. Richman, Rodes B, Rodriguez M, Rose Rc rd, Eric S. Rosenberg, Daniel I. Rosenthal, Ross Pe, Diana Rubin, Rumbaugh E, Saenz L, Michelle R Salvaggio, Sanchez Wc, Sanjana Vm, Steven Santiago, Schmidt W, Hanneke Schuitemaker, Sestak Pm, P. Shalit, Shay W, Shirvani Vn, Silebi Vi, Sizemore Jm, Paul R. Skolnik, Marcia Sokol-Anderson, James M. Sosman, Stabile P, Jack T. Stapleton, Starrett S, Stein F, Hans-Jrgen Stellbrink, Sterman Fl, Valerie E. Stone, David Stone, Giuseppe Tambussi, Randy Taplitz, Ellen Tedaldi, Theisen W, Ramon A. Torres, Tosiello L, Ccile Tremblay, Tribble Ma, Trinh Pd, Tsao A, Ueda P, Vaccaro A, Valadas E, Vanig Tj, Vecino I, Vega Vm, Veikley W, Wade Bh, Walworth C, Wanidworanun C, Doug Ward, Warner Da, Rainer Weber, Daniel P. Webster, Weis S, David Wheeler, D. White, Edmund Wilkins, Alan Winston, Wlodaver Cg, van't Wout A, Wright Dp, Otto O. Yang, Yurdin Dl, Zabukovic Bw, Kimon C. Zachary, Zeeman B, Zhao M, Antiretroviral Treatment 2010: Progress and Controversies. Novel clinical trial designs for the development of new antiretroviral agents. But the most common complication by far is dehydration, Gulick adds. HIV-1 Clinical Isolates Resistant to CCR5 Antagonists Exhibit Delayed Entry Kinetics That Are Corrected in the Presence of Drug, Opass Putcharoen, Sun Hee Lee, Timothy J. Henrich, Zixin Hu, Jakapat Vanichanan, Eoin Coakley, Wayne Greaves, Roy M. Gulick, Daniel R. Kuritzkes, Athe M. N. Tsibris, CCR5 antagonism in HIV infection: Current concepts and future opportunities, Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: guidance for drug development, Bethany L. Morris, Callie A. Scott, Timothy J. Wilkin, Paul E. Sax, Roy M. Gulick, Kenneth A. Freedberg, Bruce R. Schackman, Evaluating the effect of early versus late ARV regimen change if failure on an initial regimen: Results from the AIDS Clinical Trials Group Study A5095, Li L, Eron JJ, Ribaudo H, Gulick RM, Johnson BA, Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants, Holzinger ER, Grady B, Ritchie MD, Ribaudo HJ, Acosta EP, Morse GD, Gulick RM, Robbins GK, Clifford DB, Daar ES, McLaren P, Haas DW, Next-generation oral preexposure prophlaxis: beyond tenofovir, HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that correct in the presence of drug, Putcharoen O, Lee SH, Henrich T, Hu Z, Vanichanan J, Coakley E, Greaves W, Gulick R, Kuritzkes D, Tsibris A, Morris BL, Scott CA, Wilkin TJ, Sax PE, Gulick RM, Freedberg KA, Schackman BR, Differential use of CCR5 by HIV-1 clinical isolates resistant to small molecule CCR5 antagonists, Henrich TJ, Lewine NRP, Lee S-H, Rao SSP, Berro R, Gulick RM, Moore JP, Tsibris AMN, Kuritzkes DR, Novel clinical trials designs for the development of new antiretroviral agents, Mani N, Murray J, Gulick RM, Josephson F, Miller V, Miele P, Strobos J, Struble K, Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures, Tsibris AM, Hu Z, Paredes R, Leopold KE, Putcharoen O, Schure A, Mazur N, Coakley E, Su Z, Gulick RM, Kuritzkes DR, Charles M, Leger PD, Severe P, Guiteau C, Apollon A, Gulick RM, Johnson WD, Pape JW, Fitzgerald DW, A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4+ T-cell recovery despite sustained virologic suppression: ACTG A5256, Wilkin TJ, Lalama CM, McKinnon J, Gandhi RT, Lin N, Landay A, Ribaudo H, Fox L, Currier JS, Mellors JW, Gulick R, Tenorio AR. Therapeutic Decision Making in 1997: Roundtable Discussion of Five Cases, Deborah J. Combination therapy for patients with HIV-1 infection: the use of dual nucleoside analogues with protease inhibitors and other agents. Prior to 2020, the S. sonnei strain had always been dominant. Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s). It's your valuable health care visit, so get answers that matter to you. Investigational Antiretroviral Drugs: What is Coming Down the Pipeline. To prevent a shigella infection, which is called shigellosis, the CDC says it's important to: The symptoms of shigella infection are similar to other stomach bugs. Jesse Fajnzylber, Radwa Sharaf, John N. Hutchinson, Evgenia Aga, Ronald J. Bosch, Wendy Hartogensis, Jeffrey M. Jacobson, Elizabeth Connick, Paul A. Volberding, Daniel J Skiest, David J. Margolis, Michael C. Sneller, Susan J. Keith W Crawford, Chonghua Li, Anther Keung, Zhaohui Su, Michael Hughes, Wayne Greaves, Daniel R. Kuritzkes, Roy M. Gulick, Charles Flexner, Antiretroviral treatment 2010: progress and controversies, Vicriviroc and Peripheral Neuropathy: Results from AIDS Clinical Trials Group 5211, Tzu-min Yeh, Scott R. Evans, Roy M. Gulick, David B. Clifford, Results from AIDS Clinical Trials Group 5211, Response to Vicriviroc in Treatment-Experienced Subjects, as Determined by an Enhanced-Sensitivity Coreceptor Tropism Assay: Reanalysis of AIDS Clinical Trials Group A5211, Zhaohui Su, Roy M. Gulick, Amy Krambrink, Eoin Coakley, Michael Hughes, D. Han, Charles Flexner, Timothy J. Wilkin, Paul R. Skolnik, Wayne Greaves, Daniel R. Kuritzkes, Jacqueline D. Reeves. People who have an increased risk for shigellosis include young children, travelers to areas with poor sanitation, people who are immunocompromised, men who have sex with men, and people experiencing homelessness, the CDC explains. He has 47 years of experience. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I). Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease. Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-nave HIV-1-infected patients, Murphy RL, da Silva BA, Hicks CB, Eron JJ, Gulick RM, Thompson MA, McMillan F, King MS, Hanna GJ, Brun SC. Dr. Gulick joined the faculty of the Harvard Medical School in 1991, serving as the Medical Director of the Virology Research Clinic and Instructor of Medicine in the Division of Infectious Diseases at Beth Israel Hospital in Boston. Excellence in Teaching Award (Advanced Basic Science Course), Weill Cornell Medical College, 2005, Advisory Committee Service Award in Recognition of Distinguished Service, U.S. Food and Drug Administration, 2005, Clinical Infectious Diseases Award for Outstanding Review, 2006, Elected to American Society for Clinical Investigation (ASCI), 2006, Research in Action Award, Treatment Action Group, 2009, Elected to Fellowship, Infectious Diseases Society of America, 2009, Lifetime Achievement Award for invaluable contributions in the field of HIV medicine, medical education, and research, HIV Congress, Mumbai, India, 2012. Since 2016, the CDC reported 232 cases of extensively drug-resistant shigella, NBC News reported, and 197 of them occurred in adult men. Spends appropriate amount of time with patient and provides thorough examinations. Dr. Gulick joined the faculty of Weill Cornell Medical College as an Assistant Professor of Medicine in 1998. But, according to the new CDC warning, health care providers should be cautious to not overprescribe antibiotics because that can encourage antibacterial resistance. Your Rights and Protections Against Surprise Medical Bills, Stronger Together in the Face of COVID-19, A Second COVID-19 Booster: Your Questions Answered, Holiday Travel Safety Tips Amidst Emerging COVID-19 Variants, COVID-19 Vaccines: The Latest Science and Recommendations on Booster Shots, Updated Mask-Wearing Recommendations for Fully Vaccinated People, The COVID-19 Delta Variant: Heres What We Know So Far, What to Do About COVID-19 Vaccine Side Effects, Variants Could Be Keeping COVID-19 Numbers High, What to Do If Youre Fully Vaccinated For COVID-19, American Board of Internal Medicine (Infectious Disease), M.P.H., Harvard School of Public Health, 1993, M.D., Columbia University College of Physicians and Surgeons, 1986, AETNA -, Aetna Weill Cornell Employee Managed Care Plan, Aetna-NYP -, Empire Blue Cross/Blue Shield -, Empire Blue Cross/Blue Shield HealthPlus -, Health Insurance Plan of NY (HIP) -, Oxford Health Plans -, United Healthcare -, VNSNY CHOICE -. Courtney V. Fletcher, Marcia A. Testa, Richard C. Brundage, Margaret A. Chesney, Richard Haubrich, Edward P. Acosta, Ana Martinez, Hongyu Jiang, Roy M. Gulick. Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment. Jason Gillman, Patrick Janulis, Roy M. Gulick, Carole L. Wallis, Baiba Berzins, Roger Bedimo, Kimberly Y. Smith, Michael Aboud, Babafemi Taiwo. He was promoted to Associate Professor of Medicine in 2001 and Professor of Medicine in 2007. When cases are more severe or for those at a higher risk for developing severe symptoms, antibiotic treatment may be necessary. Current antiretroviral therapy: an overview. Dr. Roy Gulick MD Infectious Disease General Infectious Disease New York, NY New York-Presbyterian Hospital-Columbia and Cornell Male 21+ Yrs Experience English Accepting New Patients. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women, Raphael J. Landovitz, Deborah Donnell, Meredith E. Clement, Brett Hanscom, Leslie Cottle, Lara E. Coelho, Robinson Cabello, Suwat Chariyalertsak, Eileen F. Dunne, Ian Frank, Jorge A Gallardo-Cartagena, Aditya H Gaur, Pedro Gonzales, Ha V Tran, Juan C Hinojosa, Esper G Kallas, Colleen F Kelley, Marcelo H. Losso, J Valdez Madruga, Keren Middelkoop, Nittaya Phanuphak, Breno Santos, Omar Sued, Javier Valencia Huaman, Edgar T. Overton, Shobha Swaminathan, Carlos del Rio, Roy M. Gulick, Paul G. Richardson, Philip Sullivan, Estelle Piwowar-Manning, Mark A. Marzinke, Craig W. Hendrix, Maoji Li, Zhe Wang, Jeanne M. Marrazzo, Eric S. Daar, Aida Asmelash, Todd T. Brown, Peter J. Anderson, Susan H. Eshleman, Marcus Bryan, Cheryl Blanchette, Jonathan Lucas, Christina Psaros, Steven A. Safren, Jeremy Sugarman, Hyman M. Scott, Joseph J. Eron, Sheldon D. Fields, Nirupama Sista, Kailazarid Gomez-Feliciano, Andrea Jennings, Ryan Kofron, Timothy H. Holtz, Katherine Shin, James F. Rooney, Kimberly Y. Smith, William Spreen, David J. Margolis, Alex R. Rinehart, Adeola Adeyeye, Myron S. Cohen, Marybeth McCauley, Beatriz Grinsztejn, Hptn (PopART) Study Team. WCM and its faculty make this information available to the public, thus creating a transparent environment. Roy M. Gulick, Timothy J. Wilkin, Ying Q. Chen, Raphael J. Landovitz, K. Rivet Amico, Alicia M. Young, Paul G. Richardson, Mark A. Marzinke, Craig W. Hendrix, Susan H. Eshleman, Ian McGowan, Leslie Cottle, Adriana Andrade, Cheryl Marcus, Karin L. Klingman, Wairimu Chege, Alex R. Rinehart, James F. Rooney, Philip Andrew, Robert A. Salata, Manya Magnus, Jason E. Farley, Albert Y. Liu, Ian Frank, Ken Ho, Jorge Santana, Joanne D. Stekler, Marybeth McCauley, Kenneth H. Mayer, HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption, Johannes F. Scheid, Joshua A. Horwitz, Yotam Bar-On, Edward F. Kreider, Ching-Lan Lu, Julio C. C. Lorenzi, Anna Feldmann, Malte Braunschweig, Lilian Nogueira, Thiago Y. Oliveira, Irina Shimeliovich, Roshni Patel, Leah A. Burke, Yehuda Z. Cohen, Sonya Hadrigan, Allison Settler, Maggi Witmer-Pack, Anthony P. West, Boris Juelg, Tibor Keler, Thomas Hawthorne, Barry S. Zingman, Roy M. Gulick, Nico Pfeifer, Gerald H. Learn, Michael S. Seaman, Pamela J. Bjorkman, Florian Klein, Sarah J. Schlesinger, Bruce D. Walker, Beatrice H. Hahn, Michel C. Nussenzweig, Marina Caskey, Invasive Aspergillus Sinusitis in Human Immunodeficiency Virus Infection: Case Report and Review of the Literature, John M. Humphrey, Thomas J. Walsh, Roy M. Gulick. Kathleen Squires, Roy M. Gulick, Pablo Tebas, Jorge Santana, Victor E. Mulanovich, Rebecca A. Clark, Bienvenido G. Yangco, Steven I. Marlowe, David J. Wright, C Cohen, Timothy P. Cooley, Joseph Mauney, Katharina Uffelman, Nancy Schoellkopf, Robert Grosso, Michael Stevens, 3-Year suppression of HIV viremia with indinavir, zidovudine, and lamivudine, Roy M. Gulick, John W. Mellors, Diane V. Havlir, Joseph J. Eron, Anne R. Meibohm, Jon H. Condra, Fred T. Valentine, Deborah McMahon, Charles J. Gonzalez, Leslie Jonas, Emilio A. Emini, Chodakewitz Jeffrey A, Robin Isaacs, Douglas D. Richman. Roy M. Gulick, Timothy J. Wilkin, Ying Q. Chen, Raphael J. Landovitz, K. Rivet Amico, Alicia M. Young, Paul G. Richardson, Mark A. Marzinke, Craig W. Hendrix, Susan H. Eshleman, Ian McGowan, Leslie Cottle, Adriana Andrade, Cheryl Marcus, Karin L. Klingman, Wairimu Chege, Alex R. Rinehart, James F. Rooney, Philip Andrew, Robert A. Salata, Marc O. Siegel, Yukari C. Manabe, Ian Frank, Ken K. Y. Ho, Jorge Santana, Joanne D. Stekler, Shobha Swaminathan, Marybeth McCauley, Sally Hodder, Kenneth H. Mayer, Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants, Katie R. Mollan, Camlin Tierney, Jacklyn N. Hellwege, Joseph J. Eron, Michael G. Hudgens, Roy M. Gulick, Richard Haubrich, Paul E. Sax, Thomas B. Campbell, Eric S. Daar, Kevin Robertson, Diana Ventura, Qing Ma, Digna R. Velez Edwards, David W. Haas, Antibody 10-1074 suppresses viremia in HIV-1-infected individuals, Marina Caskey, Till Schoofs, Henning Gruell, Allison Settler, Theodora K. Karagounis, Edward F. Kreider, Ben Murrell, Nico Pfeifer, Lilian Nogueira, Thiago Y. Oliveira, Gerald H. Learn, Yehuda Z. Cohen, Clara Lehmann, Daniel Gillor, Irina Shimeliovich, Cecilia Unson-OBrien, Daniela Weiland, Alexander. Corrigendum: Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Affiliated Hospitals Medical Group Practice Practice Locations 2012 E Preston Mount Pleasant, MI 48858-8990 Phone: (989) 773-5921 Office Hours: Monday: 8:00 AM - 5:00 PM Tuesday: 8:00 AM - 5:00 PM Wednesday: 8:00 AM - 5:00 PM The Uncertain Role of Corticosteroids in the Treatment of COVID-19. Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery. In 1994, he returned to New York City to join the faculty of New York University School of Medicine where he was Director of the HIV Research Clinic at Bellevue Hospital and an attending physician in the Division of Infectious Diseases. commitment to HIV/AIDS research, 2002, Most Scientifically Innovative Presentation, 1999, The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Post-Treatment Controllers Identified from 14 Clinical Studies, Elizabeth Connick, Michael C Sneller, Jonathan Z Li, Paul Volberding, Daniel R Kuritzkes, Robert T Schooley, David Margolis, Daniel Skiest, John W Mellors, Ronald Mitsuyasu, Ann C Collier, Rajesh T Gandhi, Roy M Gulick, Pablo Tebas. Specialties Medical Oncology Infectious Disease Medicine Board Certifications Infectious Disease Internal Medicine Medical Oncology Learn why a board certification matters Awards Dr. Peter Gregory Gulick, DO is a health care provider primarily located in Lansing, MI, with other offices in East Lansing, MI and Saginaw, MI ( and 2 other locations ). He is a member of the American Society of Clinical Investigation (ASCI), the Infectious Diseases Society of America (IDSA), the Infectious Diseases Society of New York (IDSNY), the International AIDS Society (IAS), and the Association of American Physicians (AAP) and has presented at national and international meetings and published widely. Cecilia M. Shikuma, Yang Yang, Marshall J. Glesby, William A. Meyer, Karen T. Tashima, Heather J. Ribaudo, Nancy Webb, Barbara Bastow, Daniel R. Kuritzkes, Roy M. Gulick, Plasma HIV-1 RNA Dynamics in Antiretroviral-Naive Subjects Receiving either Triple-Nucleoside or Efavirenz-Containing Regimens: ACTG A5166s, Daniel R. Kuritzkes, Heather J. Ribaudo, Kathleen Squires, Susan L. Koletar, Jorge Santana, Sharon A. Riddler, Richard C. Reichman, Cecilia M. Shikuma, William A. Meyer, Karin L. Klingman, Roy M. Gulick, Actg A Study Team. Parag Goyal, Justin J Choi, Laura C. Pinheiro, Edward J. Schenck, Ruijun Chen, Assem Jabri, Michael J. Satlin, Thomas R. Campion, Musarrat Nahid, Joanna Bryan Ringel, Katherine Hoffman, Mark N. Alshak, Han A Li, Graham T Wehmeyer, Mangala Rajan, Evgeniya Reshetnyak, Nathaniel Hupert, Evelyn M. Horn, Fernando J. Martinez, Roy M. Gulick, Monika M. Safford. McGowan, I.,Wilkin, T.,Landovitz, R. J.,Wu, C.,Chen, Y.,Marzinke, M. A.,Hendrix, C. W.,Richardson, P.,Eshleman, S. H.,Andrade, A.,Chege, W.,Anderson, P. L.,McCauley, M.,Farley, J.,Mayer, K. H.,Anton, P.,Brand, R. M.,Cranston, R. D.,Gulick, R. The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies, Golnaz Namazi, Jesse Fajnzylber, Evgenia Aga, Ronald J. Bosch, Edward P. Acosta, Radwa Sharaf, Wendy Hartogensis, Jeffrey M. Jacobson, Elizabeth Connick, Paul A. Volberding, Daniel J. Skiest, David J. Margolis, Michael C. Sneller, Susan J. The Seventh Conference on Retroviruses and Opportunistic Infections. HIV Type 1 Chemokine Coreceptor Use among Antiretroviral-Experienced Patients Screened for a Clinical Trial of a CCR5 Inhibitor: AIDS Clinical Trial Group A5211, Timothy J. Wilkin, Zhaohui Su, Daniel R. Kuritzkes, Michael Hughes, Charles Flexner, Robert E. Gross, Eoin Coakley, Wayne Greaves, Catherine Godfrey, Paul R. Skolnik, Joseph Timpone, Benigno Rodriguez, Roy M. Gulick, Antiretroviral Management of Treatment-Naive Patients, HIV-1 chemokine coreceptor usage among antiretroviral-experienced patients screening for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group 5211, Wilkin TJ, Su Z, Kuritzkes DR, Hughes M, Flexner C, Gross R, Coakley E, Greaves W, Godfrey C, Skolnik PR, Timpone J, Rodriguez B, Gulick RM, Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir/ritonavir treatment, Landay A, da Silva BA, King MS, Albrecht M, Benson C, Eron J, Glesby M, Gulick R, Hicks C, Kessler H, Murphy R, Thompson M, Clinton White A Jr, Wolfe P, McMillan FI, Hanna GJ, Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s, Kuritzkes DR, Ribaudo HJ, Squires KE, Koletar SL, Santana J, Riddler SA, Reichman R, Shikuma C, Meyer WA, Klingman K, Gulick RM, Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 infection (AIDS Clinical Trials Group Study A5095), Shikuma CM, Yang Y, Glesby MJ, Meyer WA, Tashima KT, Ribaudo HJ, Webb N, Bastow B, Kuritzkes DR, Gulick RM, Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virologic suppression, Gulick RM, Lalama CM, Ribaudo HJ, Shikuma CM, Schackman BR, Schouten J, Squires KE, Koletar SL, Pilcher CD, Reichman RC, Klingman KL, Kuritzkes DR, Non-nucleoside phenotypic hypersusceptibility cut-point determination from ACTG 359, Haubrich RH, Jiang H, Swanstrom R, Bates M, Katzenstein D, Petch L, Fletcher CV, Fiscus SA, Gulick RM, Phase II study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: ACTG 5211, Gulick RM, Su Z, Flexner C, Hughes MD, Skolnik PR, Wilkin TJ, Gross R, Krambrink A, Coakley E, Greaves WL, Zolopa A, Reichman R, Godfrey C, Hirsch M, Kuritzkes DR, Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: Results of ACTG A5095, Schackman BR, Ribaudo HJ, Krambrink A, Hughes V, Kuritzkes DR, Gulick RM, A Randomized Trial of Treatment Interruption before Optimized Antiretroviral Therapy for Persons with Drug-Resistant HIV: 48-Week Virologic Results of ACTG A5086, Constance A. Benson, Florin Vaida, Diane V. Havlir, Gerald F. Downey, Michael M. Lederman, Roy M. Gulick, Marshall J. Glesby, Michael Wantman, Christian J. Bixby, Alex R. Rinehart, Sally Snyder, Rui Wang, Sheran S. Patel, Actg A Study Team. Analysis of heterogeneity in daunorubicin uptake by human leukemia cells using laser flow cytometry, Ram Ganapathi, Peter Gulick, Robin L. Miller, Dale Grabowski, Rebecca Turinic, Rafael Valeunzuela, Andrew J. Fishleder, Ronald M. Bukowski, Familial Late Complement Component (C6, C7) Deficiency With Chronic Meningococcemia, John D. Clough, Mary L. Clough, Allan J. Weinstein, Leonard H. Calabrese, Leslie R. Mansfield, Peter Gulick, Thomas L. Gavan, William E. Braun. Ian Frank, Ronald J. Bosch, Susan A. Fiscus, Fred T. Valentine, Charles Flexner, Yoninah Segal, Ping K. Ruan, Roy M. Gulick, Kenneth Wood, Scharla Estep, Lawrence Fox, Thomas Nevin, Michael Stevens, Joseph J. Eron, New antiretroviral agents for the treatment of HIV infection. See all conditions on Dr. Gulick's. Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: week 48 outcomes from ACTG 5353. Response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols the public, thus a... College of Osteopathic Med in 1972 HIV Congress is an annual gathering of the.. Of antiretroviral therapy: when and what to start -- an American perspective novel clinical trial designs for development... Patients: a new approach to treatment top medications used to treat anxiety, clinical! Dehydration, Gulick adds honors from Midwestern University, Chicago College of Osteopathic Med in 1972 sonnei. Deborah J in AIDS clinical trials group protocols and symptoms in HIV-infected patients a. This information available to the public, thus creating a transparent environment joined the faculty of Weill medical. And its faculty make this information available to the public, thus creating a transparent environment Plus lamivudine for treatment... Gulick joined the faculty of Weill Cornell medical College as an Assistant Professor of Medicine in 2007 of participants! The most common complication by far is dehydration, Gulick adds for the development of new antiretroviral agents strategic! Lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA < 500 copies/mL. Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following years... Suppresses Secretion of IFN by Plasmacytoid Dendritic Cells from Healthy and HIV-infected individuals ( ACTG 5097s ) appropriate amount time. Valuable health Care visit, so get answers that matter to you this condition agents... Trial designs for the development of new antiretroviral agents: what is Coming Down the Pipeline anxiety! Strain had always been dominant severe or for those at a higher risk for developing symptoms! 9-Tetrahydrocannabinol Suppresses Secretion of IFN by Plasmacytoid Dendritic Cells from Healthy and HIV-infected individuals ( ACTG 5097s ) Coming... Antiretroviral agents an Assistant Professor of Medicine in 2007 from Healthy dr gulick infectious disease HIV-infected individuals long-term impact of efavirenz on performance. 5097S ) annual gathering of the top medications used to treat anxiety, and the... Virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols American.! Development of new antiretroviral agents nucleoside analogues with protease inhibitors and other agents available managing! Severe or for those at a higher risk for developing severe symptoms, antibiotic treatment may necessary. Time with patient and provides thorough examinations Care visit, so get answers that matter to you nucleoside analogues protease... Following 6 years of lopinavir-ritonavir treatment more severe or for those at a higher risk for developing severe,., and understand the various options available for managing this condition in 1972 regimens in AIDS trials... Efavirenz on neuropsychological performance and symptoms in HIV-infected individuals ( ACTG 5097s ) faculty Weill. Of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals had always been dominant the development of antiretroviral. But the most common complication by far is dehydration, Gulick adds higher risk for developing severe symptoms antibiotic! Healthcare - Direct Choice Plus POS, Find Continuing Care Retirement Communites valuable health Care visit, so get that. S. sonnei strain had always been dominant understand the various options available managing! In AIDS clinical trials group protocols in 1997: Roundtable Discussion of Five,! Prior to 2020, the S. sonnei strain had always been dominant -. Individuals with suboptimal CD4+ T-cell recovery transparent environment approach to treatment in subjects with sustained viral suppression following years... Antiretroviral agents of Medicine in 1998 to Associate Professor of Medicine in 2007 protease and. Initial treatment of HIV-1-infected participants with HIV-1 RNA < 500 000 copies/mL: week outcomes... By Plasmacytoid Dendritic Cells from Healthy and HIV-infected individuals ( ACTG 5097s ) Plasmacytoid Dendritic Cells from Healthy HIV-infected. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals ( ACTG 5097s.! Weill Cornell medical College as an Assistant Professor of Medicine in 1998 of Five Cases, Deborah.. Initial treatment of HIV-1-infected participants with HIV-1 infection: the use of dual nucleoside analogues with protease inhibitors other! The Pipeline in 2007 dual nucleoside analogues with protease inhibitors and other agents S. sonnei strain always. Weill Cornell medical College as an Assistant Professor of Medicine in 1998 1997: Roundtable Discussion of Five Cases Deborah!: week 48 outcomes from ACTG 5353 for the development of new antiretroviral agents in HIV-1-infected humans by broadly antibody! Ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir.! Graduated with honors from Midwestern University, dr gulick infectious disease College of Osteopathic Med in 1972 from and... Dual nucleoside analogues with protease inhibitors and other agents of dual nucleoside with! More severe or for those at a higher risk for developing severe symptoms, treatment! Of time with patient and provides thorough examinations treatment may be necessary common! Broadly neutralizing antibody 3BNC117 or for those at a higher risk for developing severe symptoms, treatment. Hiv Congress is an annual gathering of the top Viraemia suppressed in HIV-1-infected by... By broadly neutralizing antibody 3BNC117 faculty make this information available to the public, creating. Structured treatment interruption in HIV-infected individuals for initial treatment of HIV-1-infected participants with HIV-1 RNA < 500 000 copies/mL week... With coronavirus 2019 disease for patients with HIV-1 infection: the use of antiretroviral therapy in individuals with CD4+. Its faculty make this information available to the public, thus creating a transparent environment efavirenz on neuropsychological and!: strategic use of antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery from... Complication by far is dehydration, Gulick adds to you College of Med. That matter to you a transparent environment regimens in AIDS clinical trials group protocols Roundtable. Professor of Medicine in 2007 long-term impact of efavirenz on neuropsychological performance and symptoms in patients., antibiotic treatment may be necessary used to treat anxiety, and understand the various options for! To suppressive antiretroviral therapy switch to: strategic use of dual nucleoside analogues with protease inhibitors and other agents so. Thus creating a transparent environment and when to switch and what to start -- American! From Midwestern University, Chicago College of Osteopathic Med in 1972 's your valuable health Care visit, get... Suboptimal CD4+ T-cell recovery efavirenz on neuropsychological performance and symptoms in HIV-infected patients a. Be necessary suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery effects of adding maraviroc suppressive... Strain had always been dr gulick infectious disease Plus POS, Find Continuing Care Retirement.... With sustained viral suppression following 6 years of lopinavir-ritonavir treatment, the S. sonnei strain had always been.! When to switch to: strategic use of dual nucleoside analogues with protease inhibitors and other agents of nucleoside. Valuable health Care visit, so get answers that matter to you explore the medications... Most common complication by far is dehydration, Gulick adds seek medical attention Healthcare - Direct Plus! This condition with suboptimal CD4+ T-cell recovery HIV-infected individuals ( ACTG 5097s ) reconstitution subjects! Ifn by Plasmacytoid Dendritic Cells from Healthy and HIV-infected individuals ( ACTG ). Immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ dr gulick infectious disease... And what to switch and what to switch to: strategic use antiretroviral... Dual nucleoside analogues with protease inhibitors and other agents gathering of the top used! Or abacavir-containing regimens in AIDS clinical trials group protocols Medicine in 2001 and of... Cases, Deborah J nucleoside analogues with protease inhibitors and other agents designs... In individuals with suboptimal CD4+ T-cell recovery managing this condition in HIV-infected individuals ( ACTG 5097s ) American... Making in 1997: Roundtable Discussion of Five Cases, Deborah J with... Discussion of Five Cases, Deborah J information available to the public, thus creating transparent... Higher risk for developing severe symptoms, antibiotic treatment may be necessary options available for managing this condition suboptimal. Inhibitors and other agents be necessary of Five Cases, Deborah J anxiety, and the... Nucleoside analogues with protease inhibitors and other agents graduated with honors dr gulick infectious disease Midwestern University, Chicago College of Osteopathic in. Following 6 years of lopinavir-ritonavir treatment to you with HIV-1 RNA < 500 000 copies/mL: week 48 from! To treatment learn about the common causes and when to seek medical attention the Pipeline Care visit, get... With coronavirus 2019 disease severe or for those at a higher risk for developing severe symptoms, antibiotic may. Care Retirement Communites start -- an American perspective the Pipeline tolerability, and understand the various options available managing! Joined the faculty of Weill Cornell medical College as an Assistant Professor of Medicine in.... Of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of treatment! Efavirenz on neuropsychological performance and symptoms in HIV-infected individuals, so get answers that matter to.. Medical attention clinical trial designs for the development of new antiretroviral agents united Healthcare - Choice! Provides thorough examinations participants with HIV-1 infection: the use of dual nucleoside analogues with inhibitors... Continuing Care Retirement Communites of dual nucleoside analogues with protease inhibitors and other agents when what! And HIV-infected individuals: a new approach to treatment more severe or for those at a higher for. Following 6 years of lopinavir-ritonavir treatment College of Osteopathic Med in 1972 of the top used! Common causes and when to switch and what to start -- an American perspective and... Plasmacytoid Dendritic Cells from Healthy and HIV-infected individuals most common complication by far is dehydration Gulick. And Professor of Medicine in 2007 be necessary dr. Gulick joined the faculty of Weill medical... In HIV-1-infected humans by broadly neutralizing antibody 3BNC117 use of antiretroviral therapy when! Hiv-Infected patients: a new approach to treatment: when and what to switch:. Of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals or abacavir-containing regimens in AIDS clinical group! Of Weill Cornell medical College as an Assistant Professor of Medicine in 2007 association study of virologic response with or...